Park Byung-Joon, Cha Mee-Kyung, Kim Il-Han
Department of Life Sciences & Technology, Paichai University, Daeduk Campus, Techno 1Ro, Daejeon, Republic of Korea.
BMC Res Notes. 2014 Jan 6;7:7. doi: 10.1186/1756-0500-7-7.
The human cytosolic thioredoxin (Trx) contains a redox-active dithiol moiety in its conserved active-site sequence. Activation by a wide variety of stimuli leads to secretion of this cytoplasmic protein. Function of Trx1 has been implicated in regulating cell proliferation, differentiation, and apoptosis. The aim of this study was to assess the clinical significance of serum Trx1 level in patients with breast carcinoma.
To clarify whether serum levels of Trx1 could be a serum marker for breast carcinoma, we measured the serum levels of Trx1 in patients with various carcinomas (breast, lung, colorectal, and kidney cancers) using an ELISA, and investigated its associations with the tumour grading from I to III. At the cut-off point 33.1725 ng/ml on the receiver operating characteristic curve (ROC) Trx1 could well discriminate breast carcinoma from normal controls with a sensitivity of 89.8%, specificity 78.0%, and area under the ROC (AUC) 0.901 ± 0.0252. The serum level was well correlated with the progress of the breast carcinoma. We also investigated the diagnostic capacity of CEA and CA15-3 for the early detection of metastatic breast cancer comparing that of Trx1. In contrast to the serum CEA and CA15-3 tumour markers, the serum Trx1 levels of the early cancer (grade I) patients were significantly higher than those of normal control subjects, showing a high diagnostic sensitivity and selectivity (89.4% sensitivity, and 72.0% specificity). The serum levels of Trx1 in various patients with lung, colorectal, and kidney carcinomas indicate that the level of Trx1 is significantly higher than those of other cancer patients. Combinational analysis of CEA or CA15-3 with Trx1 for the detection of breast cancer suggest that the diagnostic capacity of CEA or CA15-3 alone for the early detection of breast cancer, especially regarding sensitivity, is significantly improved by its combination with Trx1.
Taken together, we conclude that serum Trx1 is useful for the early diagnosis of breast cancer or the early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker and companion marker to CEA and CA15-3 for breast cancer.
人胞质硫氧还蛋白（Trx）在其保守的活性位点序列中含有一个具有氧化还原活性的二硫醇部分。多种刺激导致这种细胞质蛋白的分泌。Trx1的功能与调节细胞增殖、分化和凋亡有关。本研究的目的是评估血清Trx1水平在乳腺癌患者中的临床意义。
为了阐明血清Trx1水平是否可作为乳腺癌的血清标志物，我们使用酶联免疫吸附测定法（ELISA）测量了各种癌症（乳腺癌、肺癌、结直肠癌和肾癌）患者的血清Trx1水平，并研究了其与I至III级肿瘤分级的相关性。在接受者操作特征曲线（ROC）上的截断点33.1725 ng/ml处，Trx1能够很好地区分乳腺癌与正常对照，灵敏度为89.8%，特异性为78.0%，ROC曲线下面积（AUC）为0.901±0.0252。血清水平与乳腺癌的进展密切相关。我们还比较了Trx1与癌胚抗原（CEA）和糖类抗原15-3（CA15-3）在早期检测转移性乳腺癌方面的诊断能力。与血清CEA和CA15-3肿瘤标志物不同，早期癌症（I级）患者的血清Trx1水平显著高于正常对照受试者，显示出高诊断灵敏度和选择性（灵敏度89.4%，特异性72.0%）。肺癌、结直肠癌和肾癌患者的血清Trx1水平表明，Trx1水平显著高于其他癌症患者。CEA或CA15-3与Trx1联合检测乳腺癌表明，CEA或CA15-3单独用于早期检测乳腺癌的诊断能力，尤其是灵敏度，通过与Trx1联合使用得到显著提高。
综上所述，我们得出结论，血清Trx1可用于乳腺癌的早期诊断或乳腺癌早期预后的预测，因此作为乳腺癌的诊断标志物以及CEA和CA15-3的伴随标志物具有重要价值。
